store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DA-3003-1 (DA-3003-1) 是一种可渗透进细胞膜且具有有效性和选择性的 Cdc25 dual specificity phosphatase 抑制剂,具有抗肿瘤活性,对 Cdc25B2、Cdc25A、Cdc25B2 和 Cdc25C具有抑制作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 489 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 882 | 现货 |
产品描述 | DA-3003-1 (DA-3003-1) is a membrane-permeable, potent and selective Cdc25 dual specificity phosphatase inhibitor with antitumor activity that inhibits Cdc25B2, Cdc25A, Cdc25B2 and Cdc25C. |
靶点活性 | CDC25B2:0.21 μM, NCI 60 cells:1.5±0.6 μM, MDA-MB-435:0.2 μM, MCF-7 cells:1.7 μM |
体外活性 |
DA-3003-1(DA-3003-1)(3-100 μM; 48 hours) exhibits an average IC50 value of 1.5 ± 0.6 μM across the NCI 60 cell panel of human tumor types. The IC50 values for human breast cancer MDA-MB-435 and MDA-N cells are 0.2 μM, while in cultured human breast MCF-7 cells, the IC50 value is 1.7 μM[1]. The relative IC50 value of DA-3003-1(DA-3003-1) against Cdc25B2 (IC50=0.21 μM) is lower than that against VHR (IC50 20 times lower and 450 times lower than 4.0 μM) or PTP1B (IC50>4.0 μM)[3]. |
体内活性 | DA-3003-1(DA-3003-1)(intravenous injection; 2, 3, and 5 mg/kg) inhibits the growth of subcutaneous human colon HT29 xenografts in SCID mice. Following a single dose of 5 mg/kg, DA-3003-1(DA-3003-1)is undetectable in plasma or tissues for more than 5 minutes. After treatment of HT29 tumor-bearing SCID mice with DA-3003-1(DA-3003-1), a greater reduction in glutathione concentration is observed in the tumor compared to the liver and kidneys, and this decrease persists for a longer duration[1]. |
别名 | NSC 663284 |
分子量 | 321.76 |
分子式 | C15H16ClN3O3 |
CAS No. | 383907-43-5 |
store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL(186.47 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1079 mL | 15.5395 mL | 31.0791 mL | 77.6977 mL |
5 mM | 0.6216 mL | 3.1079 mL | 6.2158 mL | 15.5395 mL | |
10 mM | 0.3108 mL | 1.554 mL | 3.1079 mL | 7.7698 mL | |
20 mM | 0.1554 mL | 0.777 mL | 1.554 mL | 3.8849 mL | |
50 mM | 0.0622 mL | 0.3108 mL | 0.6216 mL | 1.554 mL | |
100 mM | 0.0311 mL | 0.1554 mL | 0.3108 mL | 0.777 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
DA-3003-1 383907-43-5 Metabolism Phosphatase NSC 663284 Inhibitor inhibitor inhibit